Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anti-HER2/HER3 DC vaccine | Anti-HER2/3 dendritic cell vaccine | HER2 (ERBB2) Vaccine 12 | Anti-HER2/HER3 DC vaccine is a dendritic cell vaccine that targets ERBB2 (HER2) and HER3, which potentially stimulates cytotoxic immune response against tumor cells expressing ERBB2 (HER2) and HER3, and may reduce tumor growth (NCI Drug Dictionary). | |
Celecoxib | Celecoxib is a COX-2 inhibitor that blocks inflammatory response and has anti-angiogenic and anti-proliferative activities (PMID: 31726219), which may lead to tumor growth inhibition (PMID: 17909047, PMID: 16740761). | |||
Interferon alpha-2b | Intron A | Alfatronol|Alfatronol|interferon alfa-2b|Sch 30500 | ||
Pembrolizumab | Keytruda | MK-3475 | Immune Checkpoint Inhibitor 151 PD-L1/PD-1 antibody 98 | Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, NSCLC and CD274 (PD-L1)-expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, cervical cancer, and triple-negative breast cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib or lenvatinib in RCC, with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemotherapy for patients with esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma, and in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-expressing (CPS>=1) cervical cancer (FDA.gov). |
Rintatolimod | Ampligen|Atvogen|Poly(I).Poly(c12,U) | Rintatolimod (Ampligen) is a synthetic dsRNA molecule that activates TLR3 and other interferon-induced proteins, which may result in increased anti-tumor immune response (PMID: 27045557, PMID: 19200817). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04348747 | Phase II | Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod Anti-HER2/HER3 DC vaccine + Celecoxib + Interferon alpha-2b + Rintatolimod | Dendritic Cell Vaccines Against Her2/Her3, Cytokine Modulation Regimen, and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | Recruiting | USA | 0 |